Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.23.00443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Luca Antonelli und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland. Hauptthemen laut MEDLINE: Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
What is the role of pcRPLND in men with retroperitoneal vital cancer after first-line chemotherapy? This question arises because of the potential predictive value of miR371 in identifying residual cancer even before pcRPLND! @cdfankhauser shared data within a multicenter cohort study redefining future practice in the miR371 era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland.
- Department of Urology, Policlinico Umberto I, Sapienza University, Rome, Italy.
- University of Lucerne, Lucerne, Switzerland.
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN.
- Division of Medical Oncology, Indiana University School of Medicine, Indianapolis, IN.
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.
ORCID-Profile: Isamu Tachibana, Nabil Adra, Clint Cary, Wade J Sexton, Aditya Bagrodia, Siamak Daneshmand, Sebastiano Nazzani, Andrea Franza, Axel Heidenreich, Ragheed Saoud, Scott Eggener, Alexey Tryakin, Mikhail Fedyanin, Walter Cazzaniga, Axel Gerdtsson, Karim Fizazi, Christian Daniel Fankhauser
Zitieren
APA
Antonelli, L., Ardizzone, D., Tachibana, I., Adra, N., Cary, C., Hugar, L., Sexton, W. J., Bagrodia, A., Mego, M., Daneshmand, S., Nicolai, N., Nazzani, S., Giannatempo, P., Franza, A., Heidenreich, A., Paffenholz, P., Saoud, R., Eggener, S., Ho, M., …, & EAU-YAU Penile and Testis Cancer Working Group (2023). Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00443
Vancouver
Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, et al. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.00443
BibTeX
@article{Antonelli2023,
author = {Antonelli, Luca and Ardizzone, Davide and Tachibana, Isamu and Adra, Nabil and Cary, Clint and Hugar, Lee and Sexton, Wade J and Bagrodia, Aditya and Mego, Michal and Daneshmand, Siamak and Nicolai, Nicola and Nazzani, Sebastiano and Giannatempo, Patrizia and Franza, Andrea and Heidenreich, Axel and Paffenholz, Pia and Saoud, Ragheed and Eggener, Scott and Ho, Matthew and Oswald, Nathaniel and Olson, Kathleen and Tryakin, Alexey and Fedyanin, Mikhail and Naoun, Natacha and Javaud, Christophe and Cazzaniga, Walter and Nicol, David and Gerdtsson, Axel and Tandstad, Torgrim and Fizazi, Karim and Fankhauser, Christian Daniel and EAU-YAU Penile and Testis Cancer Working Group, EAU-YAU Penile and Testis Cancer Working Group},
title = {Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.23.00443}
}
EUVIMED